Ginkgo, in search of more cell therapy tools, buys another startup

April 2, 2024

Ginkgo Bioworks is expanding its ability to help other companies make cell and gene therapies, this time by acquiring a startup with tools to improve cell-based treatments.

Ginkgo on Tuesday announced it has bought Modulus Therapeutics, a Seattle-based biotechnology startup. Ginkgo didn’t disclose the financial terms, but noted in a statement that the technology Modulus owns has the potential to boost the safety and efficacy of cell therapies.

Read More on Biopharma Dive